Sonnet biotherapeutics announces early safety data from the company's phase 1b/2a clinical trial of son-080 in chemotherapy-induced peripheral neuropathy (cipn) met the study's initial pre-specified objective

Safety in the phase 1b part of sonnet's double-blind, randomized, controlled trial of son‑080 was reviewed by the study's data safety monitoring board (dsmb) the adverse event profile and tolerability of son-080 was consistent with data from previous il-6 candidates, meeting the phase 1b safety objective sonnet will leverage this safety data to support initiation of a phase 2 clinical trial in diabetic peripheral neuropathy (dpn), a much larger indication, after a potential partnership is put in place princeton, nj / accesswire / march 11, 2024 / sonnet biotherapeutics holdings, inc. ("sonnet" or the "company"), (nasdaq:sonn) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the first phase 1b/2a clinical trial of son-080 was cleared to proceed to phase 2 after review by the independent dsmb. this study (sb211, nct05435742) is being conducted at two sites in australia in patients with persistent cipn using a new proprietary version of recombinant human interleukin-6 (rhil-6), which required confirmation of safety before continued development in phase 2.
SONN Ratings Summary
SONN Quant Ranking